Cargando…
Comparing cost of intravenous infusion and subcutaneous biologics in COVID‐19 pandemic care pathways for rheumatoid arthritis and inflammatory bowel disease: A brief UK stakeholder survey
OBJECTIVES: One important group of people at higher risk from the SARS‐CoV‐2(COVID‐19) pandemic are those with autoimmune conditions including rheumatoid arthritis/inflammatory bowel disease. To minimise infection risk, many people have been switched from intravenous to subcutaneous biologics includ...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley and Sons Inc.
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8236906/ https://www.ncbi.nlm.nih.gov/pubmed/33963659 http://dx.doi.org/10.1111/ijcp.14341 |